Skin involvement in systemic sclerosis: rituximab

References

Bosello SL, De Luca G, Rucco M et al. (2015) Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Seminars in Arthritis and Rheumatism 44: 428–36

Daoussis D, Liossis SC, Tsamandas AC et al. (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49: 271–80

Daoussis D, Liossis SC, Tsamandas AC et al. (2012) Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clinical and Experimental Rheumatology 30 (Suppl 71): S17–22

Daoussis D, Melissaropoulos K, Sakellaropoulos G et al. (2016) A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Seminars in Arthritis and Rheumatism

Denton CP, Hughes M, Gak N et al. (2016) British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guideline for the treatment of systemic sclerosis. Rheumatology 55: 1906–10

Gazi H, Pope J, Clements P et al. (2007) Outcome measurements in scleroderma: results from a Delphi exercise. The Journal of Rheumatology 34: 501–9

Jordan S, Distler JHW, Maurer B et al. (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic Diseases 74: 1188–94

Lafyatis R, Kissin E, York M et al. (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis and Rheumatism 60: 578–83

Melsens K, De Keyser F, Decuman S et al. (2016) Assessment of sensitivity to change of the European Scleroderma Study Group activity index. Clinical and Experimental Rheumatology 34 (Suppl 100): 148–51

Redelmeier DA and Lorig K (1993) Assessing the clinical importance of symptomatic improvements. Archives of Internal Medicine 153:1337–42